 | • レポートコード：MRC2103C070 • 出版社/出版日：Mordor Intelligence / 2021年2月25日 • レポート形態：英文、PDF、121ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査資料では、世界の創薬市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、医薬品別（小分子薬、バイオ医薬品）分析、技術別（ハイスループットスクリーニング、ファーマコゲノミクス、コンビナトリアルケミストリー、ナノテクノロジー、その他）分析、エンドユーザー別（製薬企業、医薬品開発業務受託機関（CRO）、その他）分析、地域別分析、競争状況、市場機会/将来の見通しなどを掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の創薬市場規模：医薬品別（小分子薬、バイオ医薬品） ・世界の創薬市場規模：技術別（ハイスループットスクリーニング、ファーマコゲノミクス、コンビナトリアルケミストリー、ナノテクノロジー、その他） ・世界の創薬市場規模：エンドユーザー別（製薬企業、医薬品開発業務受託機関（CRO）、その他） ・世界の創薬市場規模：地域別 ・競争状況 ・市場機会/将来の見通し |
The Drug Discovery Market is expected to register a CAGR of nearly 8.3% during the forecast period, with a revenue of approximately USD 53,855 million in 2020 and expected to reach 85,785 million by 2026.
Amid the COVID-19 pandemic, the health system of countries is rapidly investing in research and development to combat the virus. Potential compounds were screened from the CHEMBL database, ZINC database, FDA approved drugs, and molecules under clinical trials. Research groups across the world have set about identifying drugs for the treatment of COVID-19, by screening both novel and existing drugs for their ability to alleviate symptoms and stem viral replication. Thus, in view of the ongoing pandemic, the drug discovery market is expected to be positively impacted by the urge to find a curb on COVID-19.
The propelling factors for the growth of the drug discovery market include the rising burden of a wide range of diseases (such as cardiovascular and CNS-related disorders), rising healthcare expenditure, and upcoming patent expiration of blockbuster drugs.
The diverse range of diseases, primarily cardiovascular disease, infectious diseases, diabetes, and kidney-related complications, has a high burden, globally. For instance, according to the estimates of the Heart Disease and Stroke Statistics 2019, an update from the American Heart Association reports that approximately 116.4 million, or 46% of adults in the United States were estimated to have hypertension.
Also, according to the American Cancer Society, in 2020, about 1.8 million new cancer cases are expected to be diagnosed, and approximately 606,520 cancer deaths might occur in the United States. Thus, the increasing burden of a diverse range of diseases among all age groups and its burden, globally, drives the demand for drug discovery and its market.
There has been an upsurge in the usage of advanced technologies, such as high throughput, bioinformatics and combinatorial chemistry for better drug candidate identification. Drug discovery has evolved significantly with emerging technologies, helping the process to become more refined, accurate, and less time consuming. The adoption of artificial intelligence systems in disease diagnostics and treatment design has started growing and is expected to witness robust growth in the coming years. For instance, on March 31, 2020, Existencia, an AI-based drug discovery company, entered into a collaborative agreement with Diamond Light Source and Scripps Research for identifying Covid – 19 antiviral therapies. It is anticipated to contribute to the growth of the market over the forecast period.
The gradual rise in the healthcare expenditure regionally helps the new pharmaceutical technology advancement. Although with high expenditure, there is a need for redirecting the resources, the transition toward better usability of healthcare expenditure for drug development is under progress.
Key Market Trends
Biologics Drug is the Segment that is Expected to Grow Fastest under Drug Type
Biologics and drugs offer several benefits, such as highly effective and potent action, fewer side effects, and the potential to actually cure the diseases rather than merely treat the symptoms, which has significantly increased the demand for these products.
The efficacy and safety of biopharmaceuticals have led to their rapid adoption by people, driving the global drug discovery market. As per the report of Pharmaceutical Research and Manufacturers of America, 2019, biopharmaceutical products have shown positive results for some of the chronic and rare diseases which has led to it’s sharp rise in the demand.
As per the study of Journal of Family Medicine and Primary care, 2020, about 12 out of 46 drugs were anticancer agents in the year 2017 and, in the year of 2018, about 23 out of 55 were anticancer drugs.
As per the same study, the number of New Drug Applications (NDA’s)/Biologic License Applications (BLA’s) registered per year has seen a significant increase over the past decade. In 2017, around 46 agents were approved while in 2018 around 59 novel agents were approved. Therefore, it is expected to further drive the market studied over the forecast period.
In the pandemic, the rising adoption of biologics due to the certain advantages associated with it, especially target specificity is boding a well for the market studied. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare therapeutics for the same. For instance, in November 2020, South Korean pharma company Samsung Biologics has entered a long-term agreement with Eli Lilly and Company to manufacture its investigational Covid-19 virus-neutralizing antibody, bamlanivimab. Therefore, it is expected to further drive the market studied over the forecast period.
North America is Expected to Hold Largest Market Share Over the Forecast Period
The North America leads the world in terms of R&D spending on pharmaceuticals. It is also the largest market for bulk drugs and finished dosage formulations. The market operates as a free economy, which is designed to implement transparent trade practices and restrict anti-competitive practices.
A major push for generic drugs and biosimilars is expected to boost the demand for specialty and complex ingredients, over the forecast period. For instance, in 2019 Biocon and Mylan jointly launched a cancer drug called Ogivri, a biosimilar to Herceptin, in the United States. Herceptin is a biologic therapeutic used for the treatment of all types of breast cancers and metastatic stomach cancers (gastric or gastroesophageal junction adenocarcinoma).
Also, in November 2019, Genesis Therapeutics announced that it raised USD 4.1 million in seed funding led by Andreessen Horowitz. This company is harnessing breakthrough AI-technology to optimize drug discovery and development.
Furthermore, the country has great opportunities for biosimilars, as biologics carry higher price. By 2020, the US market is estimated to become one of the major competitors of biosimilars. The key products in the US market are Remicade, Enbrel, Rituximab, Adalimumab, Infliximab, Etanercept, Darbepoetin Alpha, etc. Hence from the aforementioned factors, the market is estimated to witness a high growth over the forecast period.
The covid-19 pandemic has highlighted the need for North American companies and research organizations to collaborate with the government to develop new drugs in order to meet future health crises. Several universities and key players are focusing on developing vaccines for coronavirus. For instance, Eli Lilly partnered with AbCellera for the development of vaccines; GSK, Novartis & MSD working with the Bill & Melinda Gates Foundation. Thus, it is expected to further boost the market studied over the forecast period.
Competitive Landscape
The market studied has various pharmaceutical companies that are investing billions of dollars in artificial intelligence (AI), in order to make the drug discovery process significantly faster and cost-efficient. The pharmaceutical and biotech companies are increasing their collaborations with contract development and manufacturing organizations; thus, playing a crucial role in the development and innovation of new drugs.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Various Chronic Diseases
4.2.2 Increasing Research and Development Expenditure and Investment for Development of Novel Drug Molecules
4.3 Market Restraints
4.3.1 Huge Capital Investment with Low Profit Margins
4.3.2 Stringent Government Regulations
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 Small Molecule Drugs
5.1.2 Biologic Drugs
5.2 By Technology
5.2.1 High Throughput Screening
5.2.2 Pharmacogenomics
5.2.3 Combinatorial Chemistry
5.2.4 Nanotechnology
5.2.5 Other Technologies
5.3 By End User
5.3.1 Pharmaceutical Companies
5.3.2 Contract Research Organizations(CROs)
5.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States (By Drug Type, By Technology, and By End User)
5.4.1.2 Canada (By Drug Type, By Technology, and By End User)
5.4.1.3 Mexico (By Drug Type, By Technology, and By End User)
5.4.2 Europe
5.4.2.1 United Kingdom (By Drug Type, By Technology, and By End User)
5.4.2.2 Germany (By Drug Type, By Technology, and By End User)
5.4.2.3 France (By Drug Type, By Technology, and By End User)
5.4.2.4 Italy (By Drug Type, By Technology, and By End User)
5.4.2.5 Spain (By Drug Type, By Technology, and By End User)
5.4.2.6 Rest of Europe (By Drug Type, By Technology, and By End User)
5.4.3 Asia-Pacific
5.4.3.1 China (By Drug Type, By Technology, and By End User)
5.4.3.2 Japan (By Drug Type, By Technology, and By End User)
5.4.3.3 India (By Drug Type, By Technology, and By End User)
5.4.3.4 Australia (By Drug Type, By Technology, and By End User)
5.4.3.5 South Korea (By Drug Type, By Technology, and By End User)
5.4.3.6 Rest of Asia-Pacific (By Drug Type, By Technology, and By End User)
5.4.4 Middle East & Africa
5.4.4.1 GCC (By Drug Type, By Technology, and By End User)
5.4.4.2 South Africa (By Drug Type, By Technology, and By End User)
5.4.4.3 Rest of Middle East & Africa (By Drug Type, By Technology, and By End User)
5.4.5 South America
5.4.5.1 Brazil (By Drug Type, By Technology, and By End User)
5.4.5.2 Argentina (By Drug Type, By Technology, and By End User)
5.4.5.3 Rest of South America (By Drug Type, By Technology, and By End User)
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Genome Biologics
6.1.2 Abbott Laboratories Inc.
6.1.3 Agilent Technologies Inc.
6.1.4 AstraZeneca PLC
6.1.5 AVIVA Biosciences
6.1.6 Bayer AG
6.1.7 Biotica Pharma
6.1.8 Bristol-Myers Squibb Company
6.1.9 Collaborative Drug Discovery Inc.
6.1.10 DeepBiome Therapeutics
6.1.11 Eli Lilly and Company
6.1.12 F. Hoffmann-La Roche Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS